InspireMD (NYSE:NSPR) Now Covered by Analysts at StockNews.com

StockNews.com started coverage on shares of InspireMD (NYSE:NSPR) in a research note issued to investors on Tuesday morning. The brokerage issued a sell rating on the stock.

InspireMD Price Performance

Shares of InspireMD stock opened at $2.09 on Tuesday. The company has a 50-day moving average of $2.44 and a 200 day moving average of $2.72. The firm has a market cap of $49.03 million, a price-to-earnings ratio of -1.94 and a beta of 0.83. InspireMD has a 1 year low of $0.96 and a 1 year high of $3.85.

InspireMD (NYSE:NSPR) last released its quarterly earnings data on Wednesday, March 6th. The company reported ($0.16) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.20) by $0.04. The business had revenue of $1.76 million during the quarter, compared to analyst estimates of $1.65 million. InspireMD had a negative net margin of 320.97% and a negative return on equity of 55.71%. During the same period last year, the business earned ($0.60) EPS. On average, equities analysts anticipate that InspireMD will post -0.61 EPS for the current year.

Institutional Trading of InspireMD

Large investors have recently modified their holdings of the stock. McKinley Carter Wealth Services Inc. purchased a new position in InspireMD during the fourth quarter worth about $28,000. Renaissance Technologies LLC purchased a new position in InspireMD in the second quarter valued at about $36,000. Avestar Capital LLC purchased a new position in InspireMD in the third quarter valued at about $65,000. Northern Trust Corp purchased a new position in InspireMD in the fourth quarter valued at about $80,000. Finally, Nantahala Capital Management LLC grew its position in shares of InspireMD by 16.9% in the fourth quarter. Nantahala Capital Management LLC now owns 2,066,456 shares of the company’s stock valued at $5,807,000 after purchasing an additional 298,406 shares during the last quarter. Hedge funds and other institutional investors own 44.78% of the company’s stock.

About InspireMD

InspireMD, Inc, a medical device company, focuses on the development and commercialization of MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system (EPS) for use in carotid artery applications; CGuard Prime Stent System, a mesh-covered self-expanding carotid stent; and SwitchGuard NPS, a non-invasive transcarotid artery revascularization device; as well as treating acute stroke with tandem lesions.